Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00512253 | Lung | MIAC | spindle assembly | 14/967 | 117/18723 | 2.84e-03 | 3.89e-02 | 14 |
GO:00328861 | Lung | MIAC | regulation of microtubule-based process | 23/967 | 240/18723 | 3.27e-03 | 4.31e-02 | 23 |
GO:004206028 | Skin | AK | wound healing | 91/1910 | 422/18723 | 2.93e-12 | 6.67e-10 | 91 |
GO:015011520 | Skin | AK | cell-substrate junction organization | 34/1910 | 101/18723 | 1.38e-10 | 2.05e-08 | 34 |
GO:003432919 | Skin | AK | cell junction assembly | 86/1910 | 420/18723 | 1.95e-10 | 2.68e-08 | 86 |
GO:000704419 | Skin | AK | cell-substrate junction assembly | 32/1910 | 95/18723 | 4.71e-10 | 5.26e-08 | 32 |
GO:000716326 | Skin | AK | establishment or maintenance of cell polarity | 53/1910 | 218/18723 | 1.32e-09 | 1.26e-07 | 53 |
GO:001081026 | Skin | AK | regulation of cell-substrate adhesion | 53/1910 | 221/18723 | 2.22e-09 | 2.02e-07 | 53 |
GO:015011620 | Skin | AK | regulation of cell-substrate junction organization | 26/1910 | 71/18723 | 2.60e-09 | 2.33e-07 | 26 |
GO:004477210 | Skin | AK | mitotic cell cycle phase transition | 83/1910 | 424/18723 | 3.81e-09 | 3.05e-07 | 83 |
GO:003158920 | Skin | AK | cell-substrate adhesion | 74/1910 | 363/18723 | 4.40e-09 | 3.30e-07 | 74 |
GO:000701528 | Skin | AK | actin filament organization | 85/1910 | 442/18723 | 5.94e-09 | 4.14e-07 | 85 |
GO:000195218 | Skin | AK | regulation of cell-matrix adhesion | 36/1910 | 128/18723 | 1.02e-08 | 6.65e-07 | 36 |
GO:005189319 | Skin | AK | regulation of focal adhesion assembly | 24/1910 | 66/18723 | 1.24e-08 | 7.83e-07 | 24 |
GO:009010919 | Skin | AK | regulation of cell-substrate junction assembly | 24/1910 | 66/18723 | 1.24e-08 | 7.83e-07 | 24 |
GO:000716019 | Skin | AK | cell-matrix adhesion | 53/1910 | 233/18723 | 1.56e-08 | 9.40e-07 | 53 |
GO:190290328 | Skin | AK | regulation of supramolecular fiber organization | 75/1910 | 383/18723 | 2.11e-08 | 1.20e-06 | 75 |
GO:003297028 | Skin | AK | regulation of actin filament-based process | 76/1910 | 397/18723 | 4.61e-08 | 2.37e-06 | 76 |
GO:001063124 | Skin | AK | epithelial cell migration | 70/1910 | 357/18723 | 5.88e-08 | 2.95e-06 | 70 |
GO:002241122 | Skin | AK | cellular component disassembly | 82/1910 | 443/18723 | 6.40e-08 | 3.16e-06 | 82 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CLASP2 | SNV | Missense_Mutation | | c.1111N>A | p.Asp371Asn | p.D371N | | protein_coding | deleterious(0.02) | probably_damaging(0.993) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
CLASP2 | SNV | Missense_Mutation | | c.293N>C | p.Ile98Thr | p.I98T | | protein_coding | tolerated(0.23) | benign(0.234) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CLASP2 | SNV | Missense_Mutation | | c.1355T>C | p.Val452Ala | p.V452A | | protein_coding | tolerated(0.06) | probably_damaging(0.954) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CLASP2 | SNV | Missense_Mutation | rs554149266 | c.1343N>A | p.Arg448Gln | p.R448Q | | protein_coding | deleterious(0.01) | probably_damaging(0.964) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CLASP2 | SNV | Missense_Mutation | novel | c.3842G>T | p.Gly1281Val | p.G1281V | | protein_coding | deleterious(0.03) | possibly_damaging(0.531) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
CLASP2 | SNV | Missense_Mutation | novel | c.179N>A | p.Gly60Glu | p.G60E | | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CLASP2 | SNV | Missense_Mutation | | c.2793N>A | p.Met931Ile | p.M931I | | protein_coding | deleterious(0.01) | benign(0.233) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CLASP2 | SNV | Missense_Mutation | | c.2897C>G | p.Ser966Cys | p.S966C | | protein_coding | deleterious(0.03) | possibly_damaging(0.54) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
CLASP2 | SNV | Missense_Mutation | novel | c.2311N>G | p.Leu771Val | p.L771V | | protein_coding | tolerated(0.17) | possibly_damaging(0.875) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
CLASP2 | insertion | Nonsense_Mutation | novel | c.2873_2874insCTAGGGATGAGGCCTACATGACCATGGTG | p.Met958IlefsTer2 | p.M958Ifs*2 | | protein_coding | | | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |